Doxorubicin (DOX)
, an anthracycline antineoplastic drug, is one of the most frequently used chemotherapeutic agents. Much is known about the biochemistry of DOX metabolism. It is reduced in cellular cytoplasm by aldehyde and ketone reductases. Detoxification probably occurs by NADPH cytochrome P450 reductase-catalysed reduction of the oxygen-linked glycoside forms to deoxyglycone forms (Difonzo et al., 1971; Bachur et al., 1974 Bachur et al., , 1979 Bachur, 1975; Benjamin et al., 1977; Oki et al., 1977; Felsted and Bachur, 1980; Gutierrez et al., 1983) . DOX and its primary alcohol metabolite doxorubicinol (DOXOL) are excreted unchanged in the bile and to a lesser extent in the urine (Difonzo et al., 1971; Bachur et al., 1974; Bachur, 1975; Benjamin et al., 1977) .
Accurate prediction of acute human clinical toxicity due to DOX by empirical determination of the plasma pharmacokinetics of DOX or its metabolites has not proved feasible (Brenner et al., 1984; Brenner, 1987; Ackland et al., 1989) . Some studies suggest that DOX-induced toxicity correlates with deranged hepatic function as measured by bromsulphophthalein time, serum bilirubin concentration or indocyanine green clearance (Benjamin et al., 1974; Benjamin, 1975; Doroshow and Chan, 1982; Brenner et al., 1984) . Hepatic dysfunction is common in cancer patients owing to factors such as hepatic metastases, drug-induced toxicity and viral and bacterial infections. Because DOX may be used for hepatic artery infusion treatment of hepatocellular carcinoma and neuroendocrne hepatic metastases (Kobayashi et al., 1986; Moertel, 1987; Kanematsu et al., 1989; Peletier et al., 1990; Venook et al., 1991; Carr et al., 1993; Ruszniewski et al., 1993) , knowledge of the hepatic pharmacokinetics of DOX is particularly relevant. Unfortunately, reports concerning the hepatic pharmacokinetics of doxorubicin are conflicting (Kaye et al., 1985) . Although some investigators have found that hepatic extraction of DOX is substantial and may be impaired by liver dysfunction (Garnick et al., 1979; Ballet et al., 1984) , others report that hepatic extraction of DOX is low and pharmacokinetic parameters are not altered when liver dysfunction is present (Chan et al., 1980; Brenner et al., 1984 Brenner et al., , 1987 Preiss et al., 1987; Munck et al., 1993) .
We have developed a swine model to study the pharmacokinetics of hepatic drug extraction and clearance (August et al., 1990; 1994) . This model permits in vivo infusion of drug either systemically or to the liver via the hepatic artery, collection of all hepatic venous effluent and removal of drug from the effluent before systemic reinfusion. This is achieved percutaneously with the use of a specially developed double-balloon catheter, which is positioned in the inferior vena cava to isolate and collect all hepatic venous blood. This method avoids the confounding pathophysiological effects of laparotomy and ex vivo perfusion, and circumvents difficulties associated with sampling blood from only a single hepatic vein. This paper reports the use of this model to study hepatic extraction and clearance of DOX.
Materal and Inthos
Hepatic venous isolation/hepatic venous drug extraction Hepatic venous isolation and hepatic venous drug extraction were accomplished using a double-balloon catheter in combination with activated charcoal filtration of drug from hepatic venous effluent. The catheter (Delcath, Stamford, CIT, USA), a four-lumen, double-balloon, polyethylene catheter, was inserted through the femoral vein by venous cutdown (August et al., 1994) . Inflation of the caudal balloon superior to the renal veins and inflation of the cephalad balloon in the suprahepatic vena cava, just below the right atrium, isolated all hepatic venous blood (Figure 1) . The blood was then withdrawn through intra-balloon catheter fenestrations into the main catheter lumen and out to an extracorporeal circuit. The fourth lumen of the catheter bypassed the main lumen and allowed blood to flow from the inferior vena cava below the caudal balloon through the catheter into the suprahepatic vena cava. All animals were sacrificed by lethal injection of Beuthanasia-D (Schering-Plough Animal Health, Kenilworth, NJ, USA) at completion of each study. At the time of sacfice, post-mortem examination was performed to ensure that the hepatic artery and double-balloon catheters were positioned properly and that no drug extravasation had occurred.
These studies were approved by the Subcommittee on Animal Studies of the Ann Arbor Veterans Administration Medical Center.
Doxorubicin administration
Clinical grade doxorubicin hydrochloride obtained from the University of Michigan Hospitals in-patient pharmac was used for all studies. Drug was administered via hepatic artery infusion to 17 swine and via systemic internal jugular vein infusion to 17 swine. In groups of three animals, swie 1rived 0.5, 1, 3, 5 or 9mg kg' DOX via either hepatic artery or systemic vein infusion over 90 mm. Hepatic venous isolation with drug extraction was performed for 240 min after initiation of hepatic artery infusions (time 0-240 min).
In swine receiving doxorubicin via systemic infusion, hepatic venous isolation for 240 min using the double-balloon catheter was performed without hepatic venous drug extraction (the fites were omitted from the extracorporeal circuit). This permitted pharmackintic isolation of the liver without altering systemic distribution of drug.
In all expeimts hepatic venous blood sampls (from the extracorporeal crcuit before filtration) and sysemic blood samples were obtained periodically for determination of doxorubicin and metabolite concentrations. In swine undergoing hepatic artery infusion/hepatic venous drug extaction, blood sMPle were also obtaied from the extracorporeal circuit after filtration to determine the efficiency of drug filtration. Samples were obtained 0, 1, 5, 10, 15, 30, 60 and 90 min after initiation of the drug infusion, and at 91, 95, 100, 105, 120, 150 and 180 min after initiation of the infusion (after completion of the infusion).
Drug analysis
High-pressure liquid chromatography (HPLC)-grade tetrahydrofuran and certified-grade ammomum formate, chloroform and ammomum sulphate were obtained from Fisher Laboratories of Allied Industries (Pittsburgh, PA, USA). A doxorubicinol standard was synthesised according to the published procedures of Takanashi and Bachur (1976) . Purity of the doxorubicn and doxorubicinol standards was confirmed by a single peak on HPLC at published retention times (Brenner et at., 1985) . The lack of other peaks in the HPLC trace at the sensitivity used suggested at las 95% purity. Specimens were assayed by HPLC after a chloroform-isopropanol (1:1, v/v) extraction according to a previously published procedure (Brenner et al., 1985 
Results
Of the 34 pigs studied, 28 survived until at least 90 min after cessation of the doxorubicin infusion (t = 180). Two pigs died from technical problems relating to the experimental procedures. The remaining four deaths occurred in pigs that received either 5 mg kg-' (two of five pigs at that dose) or 9 mg kg-' (two of two pigs at that dose) of DOX by systemic infusion. Post-mortem examination of these pigs demonstrated stigmata of acute DOX toxicity (pulmonary oedema and hepatic congestion). In the single pig receiving DOX 9 mg kg-' via systemic infusion in which serum levels were measured, the systemic AUC at 100 min (just before death) was 3890 gmmin, more than 3-fold higher than any other AUCs measured in these experiments.
Time-concentration curves (Figure 2 ) Time-concentration curves were plotted for each sampling location at each infusion dose. During hepatic arterial infusion of DOX with simultaneous hepatic venous drug extraction in the extracorporeal circuit, hepatic vein drug concentrations were approximately 2-to 10-fold greater than those measured systemically at all time points and at all infusion doses (Figure 2 ). This was true even after discontinuation of the drug infusion at 90 min. These differences were not statistically significant. During systemic infusion of DOX, systemic drug concentrations were consistently 2-to 5-fold greater than those measured in hepatic vein blood. After the systemic DOX infusion was discontinued, drug concentrations measured in hepatic vein blood generally exceeded those observed systemically (Figure 2) . Again, these differences were not statistically significant.
Except in pigs receiving DOX at the 9 mg kg-' dose, DOX metabolites rarely appeared in hepatic vein blood before 90 min. The metabolite observed most commonly was doxorubicinol, at concentrations always less than 5% of simultaneous DOX concentrations. Aglycone metabolites were seen less frequently and at even lower concentrations. Area under tine-concentration curves (AUCs, Figure 3 ) Mean AUCs were determined at each sampling location for each infusion dose by averaging the individual AUCs for each pig. As expected, AUCs measured in hepatic venous blood and systemically increased with increasing infusion dose (Table I ). In pigs receiving DOX via hepatic artery infusion with concurrent hepatic venous drug extraction, hepatic vein drug exposure was 4-to 10-fold greater than systemic drug exposure (Figure 3a) . In pigs receiving DOX via systemic infusion, systemic drug exposure exceeded hepatic vein exposure by a factor of approximately 2 ( Figure  3b ).
Filter extraction and clearance of doxorubicin (Table I) The filters used for hepatic venous DOX extraction in pigs receiving drug via hepatic artery infusion were effective. Filter extraction ratios of DOX ranged from 0.74 to 0.91, generally exceeded 0.84 between times 0 and 180m, and did not vary with time or dose.
Hepatic extraction and clearance of doxorubicin (Table I) Hepatic extraction and clearance of DOX in relation to time after initiation of drug infusion are shown in (Skibba and Condon, 1983; Skibba et at., 1983; Sindelar, 1985) allowed recirculation of some DOX to the liver via the portal crculation.
The hepatic extraction ratios and hepatic clarances of DOX measured dffered from those reported in the literature using other model systems. In a study of five patients with liver metastases from breast cancer and two patients with carcinoma of the bile duct, Garnick et al. (1979) (Greene et al., 1983) , the greater affinity of DOX for DNA as opposed to plasma (and, presumably, other extl r sites) ensues that the bulk of DOX will initially be found intacdllularly (Myers and Chabner, 1990 (Eichholtz-Wirth, 1980; Legha, 1982: Myers and Chabner, 1990 Hepatic artery infusion with hepatic venous drug extraction, however, achieved these hepatic vein AUCs with 5.7-to 23-fold lower systemic exposure than observed during systemic DOX infusion. It is possible that this pharmacokinetic benefit may be exploited to take advantage of the doxorubicin therapeutic dose-response curve in the liver while avoiding increased systemic exposure.
In summary, these data demonstrate that hepatic extraction and clearance of DOX during either systemic or hepatic artery drug infusion in pigs with normal liver function are higher than previously suspected. Furthermore, during either systemic or hepatic artery infusion of DOX, the liver serves as a reservoir for drug. Following completion of drug infusion. hepatic release of DOX results in prolonged systemic exposure to drug. Because both therapeutic and toxic effects of DOX are thought to be related to systemic AUC, the data suggest that hepatic pooling of DOX must be considered when attempting to optimise DOX efficacy. Finally, the pharmacokinetic advantages of hepatic artery infusion of DOX combined with hepatic venous drug extraaction may provide sufficient rationale to reconsider regional DOX administration for the treatment of intrahepatic malignancies.
